Corneal nerve fiber measures, neurophysiological tests and microvascular complications at the baseline and endpoint in patients with type 2 diabetes treated with or without sodium glucose cotransporter-2 inhibitor and at the baseline in control subjects. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.